Resources

×

  • Immunology

Messaging Playbooks

Monitor Payer Messaging Perception: Rheumatoid...

In addition to outlining five ways to optimize your message strategy and drive sales, this playbook also includes real messages and payer reactions in rheumatoid arthritis.

Market Access Downloads

Psoriasis

MMIT’s Market Access Downloads combine payer perceptions from Message Monitor and coverage data from Analytics.

Market Access Downloads

Rheumatoid Arthritis

MMIT’s Market Access Downloads combine payer perceptions from Message Monitor and coverage data from Analytics.

Market Access Downloads

Crohn’s Disease

MMIT’s Market Access Downloads combine payer perceptions from Message Monitor and coverage data from Analytics.

Market Access Downloads

Ulcerative Colitis

MMIT’s Market Access Downloads combine payer perceptions from Message Monitor and coverage data from Analytics.

Indication Brief Excerpts

Rheumatoid Arthritis

This excerpt gives a sneak preview of the report, which combines in-depth narratives with data-rich charts to provide current insights about a single indication, sourced from the industry-leading Biologics and Oncology Indices.

Webinars

Meet the Expert: Understanding the...

Explore how we can expect the market to react and how factors such as launch timing, interchangeability, and contracting will shape the immunology landscape.

P&T Sessions

Immunology Biosimilars: Webcast

MMIT recently held a syndicated 90-minute Webcast including the key faculty from our P&T panel, alongside key physician experts.

P&T Sessions

Ulcerative Colitis

MMIT recently held a syndicated, simulated P&T session focused on the approvals of mirikizumab and filgotinib, and the launch of Amjevita (biosimilar Humira).

P&T Sessions

How Will Existing Contracts With...

P&T Session Immunology Biosimilars: MMIT recently held a syndicated 90-minute Webcast including the key faculty from our P&T panel, alongside key physician experts.

P&T Sessions

How Do Payers See The...

P&T Session Immunology Biosimilars: MMIT recently held a syndicated 90-minute Webcast including the key faculty from our P&T panel, alongside key physician experts.

P&T Sessions

Could Manufacturers Entice Payers to...

P&T Session Immunology Biosimilars: MMIT recently held a syndicated 90-minute Webcast including the key faculty from our P&T panel, alongside key physician experts.

P&T Sessions

How Will Portfolio Contracting Impact...

P&T Session Immunology Biosimilars: MMIT recently held a syndicated 90-minute Webcast including the key faculty from our P&T panel, alongside key physician experts.

P&T Sessions

How Will The Existence Of...

P&T Session Ulcerative Colitis: MMIT recently held a syndicated, simulated P&T session focused on the approvals of mirikizumab and filgotinib, and the launch of Amjevita (biosimilar Humira).

P&T Sessions

As New Entrants Prepare To...

P&T Session Ulcerative Colitis: MMIT recently held a syndicated, simulated P&T session focused on the approvals of mirikizumab and filgotinib, and the launch of Amjevita (biosimilar Humira).

P&T Sessions

How Does The Impending Launch...

P&T Session Ulcerative Colitis: MMIT recently held a syndicated, simulated P&T session focused on the approvals of mirikizumab and filgotinib, and the launch of Amjevita (biosimilar Humira).

P&T Sessions

How Will The Complexity Of...

P&T Session Ulcerative Colitis: MMIT recently held a syndicated, simulated P&T session focused on the approvals of mirikizumab and filgotinib, and the launch of Amjevita (biosimilar Humira).

Title

Description